-
公开(公告)号:US20250163172A1
公开(公告)日:2025-05-22
申请号:US19033609
申请日:2025-01-22
Inventor: Sanjay KHANDEKAR , Patrick MAYES , Joanna OPALINSKA
IPC: C07K16/28 , A61K31/573 , A61K31/69 , A61K39/00 , A61K39/395 , A61K47/68 , A61P35/00 , C07K16/30 , C07K19/00
Abstract: Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and a proteasome inhibitor (e.g. bortezomib). The combinations can also include an anti-inflammatory compound (e.g. dexamethasone).
-
公开(公告)号:US20250160636A1
公开(公告)日:2025-05-22
申请号:US18835384
申请日:2023-02-07
Inventor: Mala Kiran TALEKAR , Jeffery Lanier PAINTER, JR.
Abstract: Aspects of the disclosure are directed to mitigating ocular toxicity in patients undergoing treatment for B-cell disorders, including cancers. Such treatment may include administering a therapeutically effective dose of a component of a B-cell disorder therapy, monitoring for signs of ocular toxicity, and, if such signs are present, adjusting the dose of that component for a subsequent administration. Monitoring for signs of ocular toxicity may include performing an ophthalmic examination of the patient, including performing a visual assessment and corneal assessment of the patient. The ophthalmic examination may include selecting visual assessment options from predefined and selectable visual assessment options and include selection corneal assessment options from predefined and selectable corneal assessment options. An overall keratopathy visual acuity (KVA) grade may be determined based on the selected visual acuity assessment options and the selected corneal assessment options.
-
公开(公告)号:US12297223B2
公开(公告)日:2025-05-13
申请号:US17606134
申请日:2020-05-06
Inventor: Michael Joseph Bishop , James Walter Janetka , Laurel Kathryn McGrane , Eugene Lee Stewart , Katherine Louisa Widdowson
IPC: C07H15/26 , C07H15/207
Abstract: Disclosed herein are new C-mannoside compounds and compositions and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in human subjects are also provided for the treatment diseases such as urinary tract infection.
-
公开(公告)号:US20250122297A1
公开(公告)日:2025-04-17
申请号:US18985239
申请日:2024-12-18
Inventor: Sanjay KHANDEKAR , Patrick MAYES , Joanna OPALINSKA
IPC: C07K16/28 , A61K31/454 , A61K31/573 , A61K39/395 , A61K47/68 , A61P35/00
Abstract: Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and an immunomodulatory drug (e.g. pomalidomide or lenalidomide). The combinations can also include an anti-inflammatory compound (e.g. dexamethasone).
-
公开(公告)号:US20250092053A1
公开(公告)日:2025-03-20
申请号:US18966276
申请日:2024-12-03
Inventor: Adam K. CHARNLEY , Janos Botyanszki , Xiaoyang Dong , Philip Gareth Humphreys , Bryan Wayne King , Kimberly Katherine Marcus , Joseph Pero , Alexander Joseph Reif , Daohua Zhang , Attiq Rahman , Kenneth Allen Newlander , Kenneth Wiggall , Joshi Ramanjulu
IPC: C07D487/04 , C07D403/14 , C07D471/04 , C07D471/14 , C07F9/6561
Abstract: The present invention relates to compounds of Formula (I), compositions containing them, and to their use in the treatment of various disorders, in particular autoimmune, autoinflammatory or immune-mediated conditions, such as systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE) and lupus nephritis.
-
公开(公告)号:US12234293B2
公开(公告)日:2025-02-25
申请号:US17846950
申请日:2022-06-22
Inventor: Sanjay Khandekar , Patrick Mayes , Joanna Opalinska
IPC: A61K39/395 , A61K31/573 , A61K31/69 , A61K47/68 , A61P35/00 , C07K16/28 , C07K16/30 , C07K19/00 , A61K39/00 , C07K14/71
Abstract: Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and a proteasome inhibitor (e.g. bortezomib). The combinations can also include an anti-inflammatory compound (e.g. dexamethasone).
-
公开(公告)号:USD1053891S1
公开(公告)日:2024-12-10
申请号:US29852639
申请日:2022-09-08
Designer: Kaushal Kishore , Mala Kiran Talekar
-
公开(公告)号:US12122828B2
公开(公告)日:2024-10-22
申请号:US18460944
申请日:2023-09-05
Inventor: Gerben Bouma , Edward Thomas Coulstock , David Dixon , Stephanie Hopley , Alan Peter Lewis , Jessica Lynn Neisen
CPC classification number: C07K16/244 , A61K2039/505 , C07K2317/92 , C07K2317/94
Abstract: Provided herein are interleukin 7 (IL-7) binding proteins, pharmaceutical compositions and their use in the treatment or prevention of a disease or condition.
-
公开(公告)号:US12043436B2
公开(公告)日:2024-07-23
申请号:US17896538
申请日:2022-08-26
Inventor: Francesco Sanmartin
CPC classification number: B65B59/04 , A61L2/04 , B65B3/003 , B65B7/2821 , B65B43/42 , B65B55/025 , A61L2202/21
Abstract: A modular production system including a plurality of production modules connected in a linear series to form a production tunnel, and collectively defining a production channel, and wherein at least one fluid inlet port defined along the production tunnel, said inlet port is in fluid communication with a pressurized fluid source, whereby influx of fluid from said fluid source through said fluid inlet port acts to maintain the fluid pressure within the production channel at a higher pressure than the atmospheric pressure outside of the production tunnel; and wherein one of said production modules positioned between said proximal-most and distal-most production modules comprises a depyrogenator and/or sterilization module, comprising a transparent tubular body, and an irradiation source positioned external to said transparent tubular body, said irradiation source capable of heating the internal environment of the depyrogenation and/or sterilization module to a temperature sufficient to depyrogenate or sterilize articles passing therethrough, and associated processes.
-
公开(公告)号:US20240180933A1
公开(公告)日:2024-06-06
申请号:US18358998
申请日:2023-07-26
Inventor: Andrew B. BENOWITZ , David T. FOSBENNER , Bryan Wayne KING , Stuart Paul ROMERIL
IPC: A61K31/675 , A61K31/44 , A61P35/02 , C07D213/85 , C07F9/58
CPC classification number: A61K31/675 , A61K31/44 , A61P35/02 , C07D213/85 , C07F9/58 , C07B2200/13
Abstract: The invention relates to substituted pyridine derivatives that are inhibitors of the activity of DNA methyltransferase 1 (DNMT1). The invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases associated with inappropriate DNMT1 activity.
-
-
-
-
-
-
-
-
-